BioSante agrees to 2.8 mln share private placement

(Reuters) - BioSante said the net proceeds will be used to continue and
expand its previously announced Phase III clinical program of
LibiGel for treatment of female sexual dysfunction.





Read more at Reuters.com Mergers News